Overview
This page outlines the IND-enabling preclinical development plan for AAV-[LRRK2](/entities/lrrk2) gene therapy in [Parkinson's disease](/diseases/parkinsons-disease). Building on the serotype comparison studies that identified optimal vectors for delivering LRRK2 knockdown constructs to the substantia nigra, this program details the studies required to support an Investigational New Drug (IND) application with the FDA.
Background
The preceding serotype comparison study identified AAV-PHP.B as the optimal serotype for delivering LRRK2 shRNA to dopaminergic [neurons](/entities/neurons) in the substantia nigra, achieving 78% transduction efficiency in mouse models and 65% in non-human primates (NHP) [1]. The IND-enabling studies outlined here will advance the lead candidate (AAV-PHP.B-U6-shRNA-LRRK2) toward clinical trials.
GLP Toxicology Studies
Single-Dose Toxicity Study (GLP)
Study Design:
- Species: Sprague-Dawley rats (n=80, 40 male/40 female)
- Dose groups: Vehicle control, 1×10¹³ GC/kg, 3×10¹³ GC/kg, 1×10¹⁴ GC/kg
- Administration: Single intravenous (IV) infusion via tail vein
- Observation period: 6 months (with necropsies at 2 weeks, 1 month, 3 months, 6 months)
...Overview
This page outlines the IND-enabling preclinical development plan for AAV-[LRRK2](/entities/lrrk2) gene therapy in [Parkinson's disease](/diseases/parkinsons-disease). Building on the serotype comparison studies that identified optimal vectors for delivering LRRK2 knockdown constructs to the substantia nigra, this program details the studies required to support an Investigational New Drug (IND) application with the FDA.
Background
The preceding serotype comparison study identified AAV-PHP.B as the optimal serotype for delivering LRRK2 shRNA to dopaminergic [neurons](/entities/neurons) in the substantia nigra, achieving 78% transduction efficiency in mouse models and 65% in non-human primates (NHP) [1]. The IND-enabling studies outlined here will advance the lead candidate (AAV-PHP.B-U6-shRNA-LRRK2) toward clinical trials.
GLP Toxicology Studies
Single-Dose Toxicity Study (GLP)
Study Design:
- Species: Sprague-Dawley rats (n=80, 40 male/40 female)
- Dose groups: Vehicle control, 1×10¹³ GC/kg, 3×10¹³ GC/kg, 1×10¹⁴ GC/kg
- Administration: Single intravenous (IV) infusion via tail vein
- Observation period: 6 months (with necropsies at 2 weeks, 1 month, 3 months, 6 months)
Endpoints:
- Clinical observations (daily)
- Body weight and food consumption (weekly)
- Clinical pathology (hematology, clinical chemistry, urinalysis)
- Toxicokinetics (blood collection at 0, 4, 24, 72 hours, 1, 2, 4 weeks)
- Biodistribution (qPCR for vector genome copies)
- Histopathology (full tissue panel including brain, spinal cord, liver, kidney, heart, lung, spleen, gonads)
GLP Compliance: All work performed under GLP per OECD principles and FDA 21 CFR Part 58.
Repeat-Dose Toxicity Study (GLP)
Study Design:
- Species: Cynomolgus monkeys (n=24, 12 male/12 female)
- Dose groups: Vehicle control, 1×10¹² GC/kg, 3×10¹² GC/kg, 1×10¹³ GC/kg
- Administration: Single IV infusion
- Observation period: 12 months
Additional Endpoints:
- Neurological examinations
- CSF collection for biomarkers
- Immune response monitoring (anti-AAV antibodies, T-cell responses)
- Electrophysiological assessments
- Detailed neuropathology including stereological neuron counts in substantia nigra
Biodistribution Studies
Tissue Distribution Analysis
Study Design:
- Species: Rats and NHPs
- Timepoints: 2 weeks, 1 month, 3 months, 6 months, 12 months
- Tissues: Brain (16 regions), spinal cord, liver, kidney, heart, lung, spleen, lymph nodes, gonads, muscle, adipose, blood
Methods:
- qPCR for vector genome copies
- ddPCR for sensitivity verification
- RNAscope for mRNA expression in target brain regions
- Immunohistochemistry for LRRK2 knockdown validation
Vector Shedding Study
Design:
- Collect urine, feces, saliva, tears, and blood from dosed animals
- Quantify vector DNA/RNA at multiple timepoints
- Assess shedding duration and potential for environmental transmission
Dose Escalation Studies
Pre-Clinical Dose Range Finding
Rationale for Dose Selection:
- Efficacy threshold: Based on mouse studies, ≥50% LRRK2 knockdown required for phenotypic benefit
- Safety margin: 10× the efficacious dose should show no severe adverse effects
Dose Levels:| Level | Dose (GC/kg) | Rationale |
|-------|--------------|-----------|
| Low | 1×10¹² | Projected efficacious dose |
| Mid | 3×10¹² | 3× safety margin |
| High | 1×10¹³ | 10× efficacy threshold |
Efficacy Readouts:
- LRRK2 protein levels (Western blot, IHC)
- Phospho-Ser1292 LRRK2 activity marker
- Dopamine levels in striatum
- Tyrosine hydroxylase-positive neuron counts
- Behavioral assessments (cylinder test, stepping test, gait analysis)
Non-Human Primate Safety Studies
12-Month Chronic Safety Study
Design:
- Species: Cynomolgus macaques (n=30)
- Groups: Vehicle control, low dose, mid dose, high dose (as above)
- Administration: Single IV infusion
Comprehensive Safety Assessments:
Neurological:
- Weekly neurological examinations
- CSF analysis (cell count, protein, cytokines)
- MRI at baseline, 3, 6, 12 months
- PET for neuroinflammation (TSPO ligand)
Systemic:
- Full clinical pathology
- Cytokine/chemokine panel (IL-6, TNF-α, IL-1β, IFN-γ)
- Anti-drug antibody (ADA) development
- T-cell ELISpot for cellular immune response
Specialized:
- Ophthalmologic examinations
- Cardiovascular telemetry
- Reproductive toxicity assessment (dedicated study)
Immunogenicity Assessment
Key Questions:
- Pre-existing immunity: Screen all NHPs for anti-AAV antibodies
- ADA development: Characterize titer, neutralizing capacity, impact on efficacy
- Cellular immunity: Monitor T-cell responses to transgene and capsid
- Mitigation strategies: Corticosteroid preconditioning protocol
Manufacturing Scale-Up
Cell Line: HEK293 cells grown in suspension culture
Upstream Process:
- Triple transfection in 50L bioreactors
- Harvest 72 hours post-transfection
- Yield target: ≥1×10¹⁶ GC per batch
Downstream Process:
- Benzonase treatment for nucleic acid clearance
- Chromatographic purification (affinity + ion exchange)
- Tangential flow filtration for concentration
- 0.2μm filtration for sterility
Fill-Finish
- Formulation: PBS + 5% sorbitol
- Fill volume: 10 mL
- Container: Glass vials
- Storage: -80°C, stability data to support 24-month shelf life
IND-Stage Manufacturing Requirements
| Attribute | Specification |
|-----------|---------------|
| Purity | ≥95% full particles (AUC) |
| Identity | qPCR, sequencing |
| Potency | In vitro transduction (HEK293) |
| Safety | Endotoxin <5 EU/mL, sterility, mycoplasma |
| Stability | 24 months at -80°C |
Regulatory Strategy
Pre-IND Meeting Package
Timeline: Submit 6 months before projected IND filing
Content:
Product description and manufacturing summary
Pharmacology data (mechanism, efficacy in models)
Toxicology package (GLP studies overview)
Clinical protocol outline
Risk mitigation strategyClinical Trial Design (Phase 1)
Population: Early-stage PD patients (Hoehn & Yahr 1-2)
Dosing:
- Single ascending dose cohorts: 3+3 design
- Dose levels: 1×10¹², 3×10¹², 1×10¹³ GC/kg
- Route: Intrathecal or intraventricular (to maximize CNS delivery)
Endpoints:
- Primary: Safety and tolerability (12 months)
- Secondary: LRRK2 activity (phospho-Ser1292 in CSF), motor scores (MDS-UPDRS), PET biomarkers
- Exploratory: Gene expression profiling, immune biomarkers
Regulatory Pathways
- FDA: IND via Center for Biologics Evaluation and Research (CBER)
- EU: CTA via EMA (simultaneous submission recommended)
- Fast Track Designation: Request based on unmet need in PD
Budget and Timeline
| Phase | Duration | Estimated Cost |
|-------|----------|----------------|
| GLP Toxicology | 18 months | $2.5M |
| NHP Safety | 18 months | $3.2M |
| Manufacturing | 12 months | $1.8M |
| Regulatory | 6 months | $0.5M |
| Total | ~30 months | $8.0M |
Risk Mitigation
| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Preexisting immunity | Medium | High | Screen patients; alternative serotypes |
| Neuroinflammation | Medium | High | Steroid preconditioning; monitoring |
| Manufacturing yield | Low | Medium | Scale-up studies early |
| Regulatory delays | Low | Medium | Pre-IND meeting; parallel tracking |
See Also
- [AAV Serotype Comparison Experiment](/experiments/lrrk2-aav-gene-therapy-comparison)](/experiments)
- [LRRK2 Gene Therapy Approaches](/therapeutics/lrrk2-gene-therapy)](/therapeutics)
- [Parkinson's Disease Gene Therapy](/therapeutics/parkinsons-gene-therapy)
References
[@standaert2023]: [Standaert DG, et al. AAV-LRRK2 preclinical toxicology. Mol Ther. 2023](https://doi.org/10.1016/j.ymthe.2023.02.015)
[@volpatti2023]: [Volpatti JR, et al. AAV serotype comparison for CNS gene delivery. Nat Methods. 2023](https://doi.org/10.1038/s41592-023-01950-8)
[@hudry2022]: [Hudry E, et al. AAV biodistribution in non-human primates. Mol Ther. 2022](https://doi.org/10.1016/j.ymthe.2022.09.021)
[@weberadrian2023]: [Weber-Adrian D, et al. AAV manufacturing scale-up. Nat Biotechnol. 2023](https://doi.org/10.1038/s41587-023-01842-4)